This article first appeared on GuruFocus.
Eli Lilly and Co. (NYSE:LLY) is making a bold long-term bet on India. The U.S. drugmaker plans to pour more than $1 billion into expanding its contract manufacturing footprint in the country over the next few yearsa move that could reshape how the company builds and distributes its blockbuster medicines worldwide. The investment includes a new manufacturing and quality center in Hyderabad, which will serve as a key technical and oversight hub for its global supply chain. Hiring for engineers, scientists, and chemists is expected to begin soon as Lilly looks to scale operations from one of the world’s fastest-growing pharma markets.
Management says the move reflects both confidence in India’s talent base and a strategic shift to diversify production capacity beyond U.S. borders. The expansion comes shortly after the company launched its high-demand diabetes drug Mounjaro in India, and follows a broader $55 billion global manufacturing buildout over the past five years. Patrik Jonsson, executive vice president and president of Lilly International, said the initiative underscores Lilly’s intent to boost supply resilience and tap into India’s role as a key hub for advanced pharmaceutical manufacturing.
The timing is significant. Just days earlier, U.S. President Donald Trump imposed a 100% tariff on imported branded and patented drugsa move that could pressure foreign producers but may leave India’s largely generic exports untouched. Still, the policy shift has intensified momentum for drugmakers like Merck and AstraZeneca, who are also ramping up U.S. and international investments. For Lilly, anchoring deeper in India could be more than a cost decisionit’s a strategic hedge against geopolitical volatility and a signal that global pharma supply chains are entering a new phase of regionalization.